Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.60    -0.35 (-4.00%)
Bid:
8.20
Ask:
9.00
Spread: 0.80 (9.756%)
Market Cap: £55.03m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Directorate Change

26 Sep 2017 07:00

RNS Number : 7668R
Kromek Group PLC
26 September 2017
 

26 September 2017

 

Kromek Group plc

("Kromek" or the "Company")

 

Directorate Change

 

Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security and nuclear markets, is pleased to announce the appointment of Christopher Wilks as Non-Executive Director of the Company with effect from 1 October 2017.

 

Christopher Wilks, 53, has considerable experience in the fields of both science and finance. He is currently Chief Financial Officer at Signum Technology, a leading group of specialised engineering businesses operating in the safety and critical service flow control sector, which he co-founded in 2012. Prior to Signum Technology, Mr Wilks was Chief Financial Officer at Sondex plc; Sondex is a specialist manufacturer of technical instruments for the oil and gas industry. Christopher became the Chief Financial Officer of Sondex in 1997 and in June 2003, he successfully managed the listing of Sondex plc on the Main Market of the London Stock Exchange. Sondex plc made several acquisitions in the period after IPO and in 2007 GE acquired Sondex; during the five years from IPO to acquisition by GE, the share price increased by a factor of 4.6 times.

 

A graduate of the University of Durham with a BSc in Applied Physics and Electronics, Christopher has had a very successful career. Initially joining Marconi Space Systems and applying his degree education in the design of power systems for space craft, Christopher then trained as a Chartered Accountant at Arthur Young (now EY). After qualifying as a Chartered Accountant in audit he became a Manager in the Corporate Finance team at Ernst & Young.

 

Sir Peter Williams, Chairman of Kromek, said: "We are delighted to welcome Christopher to the Board as Non-Executive Director. His intimate understanding of the physics and financial worlds will add valuable insight and expertise. Christopher's impressive record of deal making and managing business growth at international manufacturing organisations will help immeasurably as we roll out our products to customers around the globe."

 

Commenting on his appointment as Non-Executive Director, Christopher Wilks said: "As a graduate of the University of Durham's physics department, I am thrilled to be joining Kromek at this exciting time for the Company. In particular, I am keen to use my international experience to support the management team objective of achieving full commercial value for its impressive radiation detection technology. I look forward to working with the Board to deliver further value for shareholders in the future."

 

Mr Wilks owns 75,000 ordinary shares in Kromek, which represents 0.03 per cent. of the current issued share capital.

 

Christopher Wilks is currently or has been a director of the following companies within the previous five years:

 

Current directorships

 

Signum Technology Ltd and its subsidiary companies, including:

Copper Midco 1 Limited

Cooper Midco 2 Limited

Cooper Bidco Limited

Gall Thomson International Limited

Klaw Products Limited

Vee Bee Limited

Vee Bee Filtration (UK) Limited

Filtration & Valves Limited

 

Past directorships

 

Falcon Oilfield Services LLC

 

Mr Wilks was a director of Clearwater Industries between 1994 and 1996. In 1996, Clearwater Industries was put into liquidation and was sold two days later. The creditor shortfall was approximately £100,000.

There is no further information required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM rules.

 

Enquiries

 

Kromek Group plc

Arnab Basu, CEO

Derek Bulmer, CFO

+44 (0)1740 626 060

Cenkos Securities plc

Bobbie Hilliam (NOMAD)

Julian Morse (Sales)

+44 (0)20 7397 8900

Luther Pendragon Ltd

Harry Chathli, Claire Norbury, Alexis Gore

+44 (0)20 7618 9100

 

 

About Kromek Group plc

 

Kromek Group plc is a UK technology Group (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT") and other advanced technologies. Using its core technology platforms, Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

The Group's business model provides a vertically integrated technology offering to customers, from radiation detector materials to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Group has operations in the UK and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over one hundred full time employees across its global operations. Further information on Kromek Group is available at www.kromek.com and https://twitter.com/kromekgroup.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALLFSDARIEFID
Date   Source Headline
4th Jun 20267:00 amRNSGrant of Long-Term Incentives
2nd Jun 20267:00 amRNS-RLaunch of new interactive investor hub
1st Jun 20267:00 amRNSPDMR/Director Shareholding, Issue of Equity & TVR
12th May 20267:00 amRNSFull Year 2026 Trading Update
30th Apr 20262:30 pmRNSIssue of Equity, TVR & Extension of Options
9th Mar 20261:36 pmRNSDirector Share Purchase
9th Mar 20261:36 pmRNSDirector Share Purchase
20th Jan 20267:00 amRNSInterim Results
16th Dec 20257:00 amRNSNotice of Results
15th Dec 202512:27 pmRNSHolding(s) in Company
3rd Nov 202511:32 amRNSDirector Share Purchase
28th Oct 20257:00 amRNSGrant of Options, PDMR Dealings and TVR
27th Oct 20252:16 pmRNSResult of AGM
27th Oct 20257:00 amRNSPre-close Trading Statement
3rd Oct 202510:06 amRNSNotice of AGM and Publication of Annual Report
16th Sep 20257:00 amRNSFinal Results
11th Aug 20257:00 amRNSNew Biosecurity Award from UK MoD
28th Jul 20257:00 amRNS$5m received under Siemens Healthineers agreement
21st Jul 20257:00 amRNS£1.7m contract win under UK Government Framework
23rd Jun 202511:40 amRNS-RCapital Markets Day Presentation
18th Jun 20257:00 amRNSCapital Markets Day
16th Jun 20254:02 pmRNSHolding(s) in Company
9th Jun 20257:00 amRNSIssue of Equity and Total Voting Rights
3rd Jun 20251:53 pmRNSHolding(s) in Company
3rd Jun 20257:00 amRNSCapital Markets Day
28th May 20257:00 amRNSNew Nuclear Security Orders
8th May 20257:05 amRNSDirectorate Change
8th May 20257:00 amRNSFull Year 2025 Trading Update
17th Feb 20257:00 amRNS$25m received under Siemens Healthineers agreement
7th Feb 20251:49 pmRNSHolding(s) in Company
6th Feb 202512:35 pmRNSHolding(s) in Company
30th Jan 20257:01 amRNSInterim Results
30th Jan 20257:00 amRNSKromek Signs Agreements with Siemens Healthineers
13th Dec 202412:20 pmRNSResult of AGM
18th Nov 20247:00 amRNSNotice of AGM and Publication of Annual Report
28th Oct 20247:01 amRNSFinal Results and Publication of Annual Report
28th Oct 20247:00 amRNSFinancing Update
30th Sep 20247:00 amRNSUpdate on Full Year Results
23rd Sep 20247:00 amRNSKromek selected for UK Government Framework
16th Sep 20247:00 amRNSKromek awarded £2.0m contract from UK MOD
21st Aug 202410:14 amRNSHolding(s) in Company
7th Jun 20249:20 amRNSCancellation of outstanding Convertible Loan Notes
29th May 20247:00 amRNSFY 2024 Trading Update
25th Apr 20247:00 amRNSKromek receives new Nuclear Security contract
3rd Apr 20243:13 pmRNSDirector/PDMR Shareholding
26th Mar 20247:00 amRNSKromek receives $2.1m security screening order
6th Mar 20243:21 pmRNSHolding(s) in Company
4th Mar 202412:16 pmRNSHolding(s) in Company
4th Mar 202411:51 amRNSResult of General Meeting
5th Feb 202410:17 amRNSConversion of £1.5m of Convertible Loan Notes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.